EligibleTrials

Clinical trials recruiting for Uveal Melanoma, Recurrent

Fewer than 3 recruiting trials found.

2
Recruiting trials
9
US states with sites
2
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 2Phase 2 1

Drugs and treatments being studied

InterventionTrials
Cemiplimab1
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.1
ONM-5011

Where trials are recruiting (top US states)

StateRecruiting trials
Arizona1
California1
Colorado1
Florida1
Ohio1
Pennsylvania1
Tennessee1
Texas1
Virginia1

Top cities

Canton, Ohio 1Columbus, Ohio 1Dallas, Texas 1Denver, Colorado 1Fairfax, Virginia 1Houston, Texas 1Los Angeles, California 1Nashville, Tennessee 1Pittsburgh, Pennsylvania 1Scottsdale, Arizona 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Uveal Melanoma, Recurrent often also study these conditions. Each links to its own recruiting-trial list.

Melanoma 487Uveal Melanoma, Metastatic 4Tumor, Solid 4Triple-negative breast cancer 138Skin Cancer 23Metastatic Uveal Melanoma 11Metastatic Cancer 31Mantle Cell Lymphoma 7Lymphoma, Non-Hodgkin 3Head and Neck Squamous Cell Carcinoma 42

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Uveal Melanoma, Recurrent trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.